Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SENTI-202 |
Trade Name | |
Synonyms | SENTI202|SENTI 202 |
Drug Descriptions |
SENTI-202 comprises allogeneic NK-cells engineered to express a chimeric antigen receptor (CAR) targeting CD33 and FLT3 along with an inhibitory CAR (iCAR) targeting EMCN on healthy hematopoietic stem cells and progenitor cells, which potentially induces a cytotoxic immune response against tumor cells expressing CD33 and/or FLT3 (Cancer Res (2023) 83 (7_Supplement): 3195). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
SENTI-202 | SENTI-202 | 0 | 1 |